Andrea BALLABIO
Lauréat du Prix Louis-Jeantet de médecine 2016

Né en 1957 à Naples (Italie), Andrea Ballabio a étudié la médecine à l’Université Frederico II de sa ville natale où il a ensuite obtenu le statut de résident en pédiatrie. Après des séjours post-doctoraux au Guy’s Hospital de Londres et à l’Institut international de génétique et biophysique à Naples, Andrea Ballabio est parti aux Etats-Unis. Il a passé plusieurs années à Houston, Texas, où il a été professeur associé au Département de génétique moléculaire et humaine du Baylor College of Medicine, puis co-directeur du Baylor Human Genome Center. Rentré en Italie en 1994, il est devenu le fondateur et le directeur de l’Institut Téléthon de Génétique et Médecine (TIGEM), institut géré par la Fondation Téléthon qui étudie les maladies génétiques rares. Il est aussi professeur de génétique médicale à l’Université Frederico II, ainsi que professeur invité au Baylor College of Medicine et à l’Université d’Oxford, en Grande-Bretagne.

Andrea Ballabio a reçu de nombreux prix et distinctions pour ses travaux. Membre du Conseil de l’Organisation européenne de biologie moléculaire (EMBO), il a été président de la Société européenne de génétique humaine qui lui a décerné son Prix international en 2007, et, la même année, il a été promu au rang de Chevalier de l’ordre du mérite par la président de la République italienne. En 2010, il a été lauréat de l’Advanced Investigator Award du Conseil européen de la recherche. Par ailleurs, il a été porte-flambeau lors des XXème Jeux Olympiques d’hiver à Turin, en 2006.

Un «chef d’orchestre» pour les lysosomes

Les lysosomes, découverts par Christian de Duve, Prix Nobel de physiologie et de médecine, jouent un rôle clé dans la vie cellulaire. Ils sont au centre de la machinerie qui nettoie la cellule en dégradant et recyclant les matériaux secondaires produits par son métabolisme. Jusqu’à une époque récente, ces organelles étaient considérées comme de simples «sacs-poubelle» intervenant dans la phase terminale du métabolisme cellulaire. Andrea Ballabio a bousculé ce dogme. Il a montré que les lysosomes agissaient comme des plaques tournantes dans les mécanismes qui régulent les processus cellulaires, en réponse aux signaux venus de l’environnement.

Le groupe d’Andrea Ballabio a découvert un gène-maître (TFEB) qui contrôle l’activité des lysosomes. Se conduisant en véritable «chef d’orchestre», il régule l’expression des nombreux autres gènes qui interviennent dans l’assainissement de la cellule. Cette découverte révèle un nouveau mécanisme biologique, mais elle a aussi des implications cliniques. En effet, la dysfonction lysosomale est à la base de maladies neurodégénératives fréquentes et de nombreuses maladies héréditaires. La recherche menée par Andrea Ballabio et son équipe ouvre ainsi la voie à de nouveaux traitements d’affections provoquées par l’accumulation dans la cellule de substances pathologiques.

Shorten and reproduced with permission from EMBO Molecular Medicine. Ballabio A (2016) “The awesome lysosome”. EMBO Mol Med doi:10.15252/emmm.201505966

The awesome lysosome

Running title: The lysosome in cell metabolism and disease

Keywords: autophagy, lysosomal storage diseases, mTORC1, TFEB, signalling

Andrea Ballabio

Telethon Institute of Genetics and Medicine (TIGEM), and Medical Genetics, Department of Translational Medicine, Federico II University, Naples, Italy;

Department of Molecular and Human Genetics, Baylor College of Medicine, and Jan and Dan Duncan Neurological Research Institute, Texas Children Hospital, Houston, TX, USA.

E.Mail: ballabio(at)tigem.it

The lysosome at a glance

Cellular organelles enable the spatial clustering of molecules, thus favoring their interactions in microenvironments ideally suited for specific complex functions. A well-known function of the lysosome is to degrade and recycle cellular waste. Extracellular materials reach the lysosome mainly through endocytosis and phagocytosis, whilst a completely
different process, autophagy, mediates
the delivery of intracellular
materials. Autophagy is activated by a broad range of cellular stress-inducing conditions and mediates the degradation of protein aggregates, oxidized lipids, damaged organelles and intracellular pathogens. The process typically involves the formation of double membrane-bound vesicles, the autophagosomes, which sequester cytoplasmic material and then fuse with lysosomes. Materials that reach the lysosome are degraded by lysosomal hydrolases and the resulting breakdown products are used to generate new cellular components and energy in response to the nutritional needs of the cell. Lysosomes are also involved in an “unconventional” secretory pathway known as lysosomal exocytosis, which plays an important role in various physiological processes such as plasma membrane repair, immune response, and bone resorption.

The lysosomal lumen has an acidic pH
close to 4.5 and contains approximately 60 different soluble hydrolytic
enzymes, which are
directly involved in the degradation of metabolites. The lysosomal membrane contains proteins such as, transporters, ion channels and SNAREs that mediate different aspects of lysosomal function, as well as the vATPase complex that mediates lysosomal acidification. In addition to lumenal and integral membrane proteins, an expanding number of proteins and of protein complexes have been found to associate, under particular conditions, to the lysosomal surface. The activity of such proteins may be either directly influenced by the lysosome, or, in turn may regulate or mediate specific aspects of lysosomal function. Notable examples are the mTORC1 kinase complex, whose activity depends on lysosomal nutrient content (Zoncu et al, 2011) and the BORC protein complex, which regulates lysosome positioning (Pu et al, 2015). We know however, the precise function of only a small fraction of the known lysosomal proteins and it is likely that additional ones remain to be identified.

The expanding role of the lysosome in human diseases

Mutations in genes encoding proteins involved in lysosomal function cause Lysosomal Storage Diseases (LSDs), a group of about 50 inherited disorders characterized by the progressive accumulation of undegraded substrates inside the lysosome. Patients with LSDs present with a debilitating, multi-systemic phenotype often associated with early-onset neurodegeneration. Unfortunately, therapeutic options are still inefficient or simply unavailable for most LSDs. How exactly the storage of undegraded material in LSDs causes cellular and tissue dysfunction and clinical symptoms has yet to be fully elucidated. A common consequence of pathological lysosomal storage is an impairment of autophagy, which leads to the secondary accumulation autophagy substrates.
Notably, the lysosome has also been found to be crucially involved in a variety of common disease conditions, such as neurodegenerative diseases, infection, obesity and cancer. Induction of the lysosomal-autophagic pathway was detected in pancreatic cancer (Perera et al, 2015). Furthermore, cancer cells were found to be more prone to lysosomal membrane permeabilization (Aits & Jaattela, 2013). In recent years, lysosomal gene mutations have been identified in an increasing number of patients with common neurodegenerative diseases, such as Parkinson’s and Alzheimer’s. For example, heterozygosity for mutations in the gene encoding glucocerebrosidase predisposes to Parkinson’s disease (Sidransky et al, 2009) via a mechanism that is still unclear. Interestingly, homozygosity for mutations in the same gene causes Gaucher disease, the most common neurodegenerative LSD.
Additionally, aggregate-prone proteins such as huntingtin and -synuclein that are involved in Huntington’s and Parkinson’s diseases, respectively, are degraded by the lysosomal-autophagic pathway and can be eliminated by inducing autophagy. These findings emphasize the importance of the lysosomal-autophagic pathway in neurodegenerative diseases and that therapeutic strategies aimed at rescuing and/or enhancing this pathway may have a broad impact on human health.

TFEB and the CLEAR network regulate lysosomal biogenesis

How the cell controls lysosomal function has remained unanswered and unexplored for a long time. A systems biology approach led to the discovery that lysosomal biogenesis and autophagy are transcriptionally regulated by a gene network, named CLEAR, and by its master gene TFEB (Sardiello et al, 2009; Settembre et al, 2011), a member of the Helix-Loop-Helix (HLH) leucine zipper family of transcription factors, providing the first evidence that lysosomal function is globally regulated and how this might occur.
We now know that TFEB plays a fundamental role in cell homeostasis and provides us with an unprecedented tool to globally induce lysosomal function and autophagy in in vitro, as well as in vivo. Overexpression of TFEB reduces the amount of accumulated substrates via the induction of the lysosomal-autophagic pathway. These include LSDs but also α1anti-trypsin deficiency and Spinal Bulbar Muscular Atrophy, as well as common diseases such as Parkinson’s, Alzheimer’s, and Huntington’s. In all cases TFEB overexpression resulted in a significant rescue of the disease phenotype (Settembre et al, 2013). Recent studies showed that another HLH transcription factor highly homologous to TFEB, TFE3, regulates a similar set of genes and is able to promote cellular clearance (Martina et al, 2014). The possibility of globally modulating lysosomal function by acting on TFEB/TFE3 and on the CLEAR network may lead to a novel therapeutic strategy with potential applicability to many diseases.

The lysosome as a signalling hub

The kinase complex mTORC1 (Mechanistic Target of Rapamycin Complex 1), a master controller of cell and organism growth, was recently shown to exert its activity on the lysosomal surface and to become inactive when released from the lysosome (Zoncu et al, 2011). mTORC1 belongs to a complex signalling machinery that responds to the lysosomal amino acid content via a nutrient sensing mechanism. Thus, the lysosome plays an important and unexpected role in cell signaling by controlling the activity of mTORC1.
Interestingly, mTORC1 regulates TFEB subcellular localization and activity. mTORC1-mediated phosphorylation of TFEB specific serine residues, which occurs on the lysosomal surface (Martina et al, 2012; Roczniak-Ferguson et al, 2012; Settembre et al, 2012), keeps TFEB inactive in the cytoplasm. Under nutrient-rich conditions active mTORC1 promotes biosynthetic pathways and blocks autophagy. A variety of stress stimuli, such as starvation and lysosomal stress, inhibit mTORC1 activity, thus inducing TFEB nuclear translocation and promoting lysosomal biogenesis and autophagy.
In addition, under energy demanding conditions, such as starvation and physical exercise, lysosomal calcium release via the lysosomal calcium channel mucolipin1 (MCOLN1) activates the calcineurin phosphatase, which in turn dephosphorylates TFEB, thus promoting its nuclear translocation and activation (Medina et al, 2015). Therefore, a lysosome-to-nucleus signaling mechanism enables lysosomal function to respond to environmental cues and regulates the switch between cellular biosynthetic and catabolic pathways (Settembre et al, 2012). These studies indicate that the lysosome acts as a signalling hub that controls cell metabolism and homeostasis.

The “lysosomics” approach

After 60 years from its discovery the lysosome has yet to reveal all its secrets. Future studies may reveal the presence of additional lysosomal regulatory networks operating at the transcriptional, post-transcriptional (e.g. microRNAs), or post- translational levels. An example of a lysosomal post-translational regulatory pathway is the regulation of sulfatases by the Sulfatase Modifying Factor 1 (SUMF1).
Lysosomal function may also be mediated by protein networks via protein-protein interactions. A few examples of such complexes have already been identified, such as the GLB1-NE1-GALNS-CTSA complex in the lysosomal lumen and the above- mentioned vATPase complex on the lysosomal membrane. Proteomic studies applied to the lysosome may reveal additional examples of such protein complexes and their function.
Another important goal is to further elucidate the signalling pathways that control lysosomal function as well as the role of the lysosome as a signalling hub. The study of these pathways may lead to the discovery of tools able to modulate lysosomal function in a sensitive and selective fashion. Functional genomic approaches (e.g. siRNA-based) and drug screenings, combined with high content cell-based assays, will play an important role in this endeavour.
Finally, we need to further define the role of lysosomal mutations as predisposing factors for human diseases. Whole genome, exome, and targeted sequencing of lysosomal genes, combined with functional analysis, may lead to the identification of new lysosomal genes whose mutations represent major determinants of the pathogenesis of a broad variety of human diseases. The Lysoplex tool (Di Fruscio et al, 2015) represents an example of a lysosome-targeted sequencing platform, which may be used to find both disease-causing mutations in LSDs and predisposing mutations in common diseases.

In conclusion, the biology and pathophysiology of the lysosome is still far from being completely understood. The integration of “omics” technologies to study the lysosome, an approach that may be termed “lysosomics”, will reveal the full potential of the awesome lysosome.

figure 1

Figure 1
A lysosome-to-nucleus signalling mechanism.
Signalling mechanisms that regulate TFEB nuclear translocation. Under normal feeding conditions, TFEB is phosphorylated by mTORC1 on the lysosomal surface and is sequestered in the cytoplasm by 14-3-3 proteins. During starvation and physical exercise MTORC1 is inactivated and Ca2+ is released from the lysosome through
MCOLN1. This leads to local calcineurin activation and TFEB dephosphorylation. Dephosphorylated TFEB
is no longer able to bind 14-3-3 proteins and can freely translocate to the nucleus where it transcriptionally activates the lysosomal/autophagic pathway [modified from (Medina et al, 2015)].

References

Aits S, Jaattela M (2013) Lysosomal cell death at a glance. J Cell Sci 126: 1905-1912 de Duve C (2005) The lysosome turns fifty. Nat Cell Biol 7: 847-849
Di Fruscio G, Schulz A, De Cegli R, Savarese M, Mutarelli M, Parenti G, Banfi S, Braulke T, Nigro V, Ballabio A (2015) Lysoplex: An efficient toolkit to detect DNA sequence variations in the autophagy-lysosomal pathway. Autophagy 11: 928-938
Martina JA, Chen Y, Gucek M, Puertollano R (2012) MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy 8: 903-914
Martina JA, Diab HI, Lishu L, Jeong AL, Patange S, Raben N, Puertollano R (2014) The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci Signal 7: ra9
Medina DL, Di Paola S, Peluso I, Armani A, De Stefani D, Venditti R, Montefusco S, Scotto-Rosato A, Prezioso C, Forrester A et al (2015) Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat Cell Biol 17: 288-299
Perera RM, Stoykova S, Nicolay BN, Ross KN, Fitamant J, Boukhali M, Lengrand J, Deshpande V, Selig MK, Ferrone CR et al (2015) Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature 524: 361-365
Pu J, Schindler C, Jia R, Jarnik M, Backlund P, Bonifacino JS (2015) BORC, a multisubunit complex that regulates lysosome positioning. Dev Cell 33: 176-188
Roczniak-Ferguson A, Petit CS, Froehlich F, Qian S, Ky J, Angarola B, Walther TC, Ferguson SM (2012) The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal 5: ra42
Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, Di Malta C, Donaudy F, Embrione V, Polishchuk RS et al (2009) A gene network regulating lysosomal biogenesis and function. Science 325: 473-477
Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, Erdin SU, Huynh T, Medina D, Colella P et al (2011) TFEB links autophagy to lysosomal biogenesis. Science 332: 1429-1433
Settembre C, Fraldi A, Medina DL, Ballabio A (2013) Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol 14: 283-296
Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Huynh T, Ferron M, Karsenty G, Vellard MC, Facchinetti V et al (2012) A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. Embo J 31: 1095-1108
Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 361: 1651- 1661
Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM (2011) mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science 334: 678-683

 

Embo Molecular Medicine

Professeur Andrea Ballabio

Telethon Institute of Genetics and Medicine (TIGEM)
Via Campi Flegrei 34
80078 Pozzuoli (Napoli)
Italy

Téléphone: +39.081.6132207207
Fax: +39.081.5790919


www.tigem.it
www.tigem.it/research/faculty/ballabio